TY - JOUR AU - Pham, N. B. AU - Meng, W. S. PY - 2020 DA - 2020// TI - Protein aggregation and immunogenicity of biotherapeutics JO - Int J Pharm VL - 585 UR - https://doi.org/10.1016/j.ijpharm.2020.119523 DO - 10.1016/j.ijpharm.2020.119523 ID - Pham2020 ER - TY - JOUR AU - Sperinde, G. AU - Montgomery, D. AU - Mytych, D. T. PY - 2020 DA - 2020// TI - Clinical immunogenicity risk assessment for a fusion protein JO - AAPS J VL - 22 UR - https://doi.org/10.1208/s12248-020-00447-y DO - 10.1208/s12248-020-00447-y ID - Sperinde2020 ER - TY - JOUR AU - Krishna, M. PY - 2020 DA - 2020// TI - Product-related factors and immunogenicity of biotherapeutics JO - J Pharm Innov VL - 15 UR - https://doi.org/10.1007/s12247-019-09423-2 DO - 10.1007/s12247-019-09423-2 ID - Krishna2020 ER - TY - JOUR AU - Kierzek, A. M. AU - Hickling, T. P. AU - Figueroa, I. AU - Kalvass, J. C. AU - Nijsen, M. AU - Mohan, K. PY - 2019 DA - 2019// TI - A quantitative systems pharmacology consortium approach to managing immunogenicity of therapeutic proteins JO - CPT Pharmacometrics Syst Pharmacol VL - 8 UR - https://doi.org/10.1002/psp4.12465 DO - 10.1002/psp4.12465 ID - Kierzek2019 ER - TY - STD TI - Yogurtcu ON, Sauna ZE, McGill JR, Tegenge MA, Yang H. TCPro: an in Silico risk assessment tool for biotherapeutic protein immunogenicity. AAPS J. 2019;21. https://doi.org/10.1208/s12248-019-0368-0. ID - ref5 ER - TY - JOUR AU - Hamuro, L. AU - Kijanka, G. AU - Kinderman, F. AU - Kropshofer, H. AU - Bu D xiu, Zepeda M, et al. PY - 2017 DA - 2017// TI - Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins JO - J Pharm Sci VL - 106 UR - https://doi.org/10.1016/j.xphs.2017.05.030 DO - 10.1016/j.xphs.2017.05.030 ID - Hamuro2017 ER - TY - JOUR AU - Pivot, X. AU - Bondarenko, I. AU - Nowecki, Z. AU - Dvorkin, M. AU - Trishkina, E. AU - Ahn, J. H. PY - 2018 DA - 2018// TI - Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.74.0126 DO - 10.1200/JCO.2017.74.0126 ID - Pivot2018 ER - TY - JOUR AU - Dingman, R. AU - Balu-Iyer, S. V. PY - 2019 DA - 2019// TI - Immunogenicity of protein pharmaceuticals JO - J Pharm Sci VL - 108 UR - https://doi.org/10.1016/j.xphs.2018.12.014 DO - 10.1016/j.xphs.2018.12.014 ID - Dingman2019 ER - TY - JOUR AU - Pimentel, F. F. AU - Morgan, G. AU - Tiezzi, D. G. AU - Andrade, J. M. PY - 2018 DA - 2018// TI - Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous Trastuzumab JO - Pharmaceut Med VL - 32 UR - https://doi.org/10.1007/s40290-018-0247-5 DO - 10.1007/s40290-018-0247-5 ID - Pimentel2018 ER - TY - JOUR AU - Ponce, R. AU - Abad, L. AU - Amaravadi, L. AU - Gelzleichter, T. AU - Gore, E. AU - Green, J. PY - 2009 DA - 2009// TI - Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies JO - Regul Toxicol Pharmacol VL - 54 UR - https://doi.org/10.1016/j.yrtph.2009.03.012 DO - 10.1016/j.yrtph.2009.03.012 ID - Ponce2009 ER - TY - JOUR AU - Bian, S. AU - Ferrante, M. AU - Gils, A. PY - 2017 DA - 2017// TI - Validation of a drug-resistant anti-Adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of Adalimumab JO - AAPS J VL - 19 UR - https://doi.org/10.1208/s12248-016-0018-8 DO - 10.1208/s12248-016-0018-8 ID - Bian2017 ER - TY - JOUR AU - Noda-Narita, S. AU - Shimomura, A. AU - Kawachi, A. AU - Sumiyoshi-Okuma, H. AU - Sudo, K. AU - Shimoi, T. PY - 2019 DA - 2019// TI - Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese popu JO - Breast Cancer VL - 26 UR - https://doi.org/10.1007/s12282-019-00949-4 DO - 10.1007/s12282-019-00949-4 ID - Noda-Narita2019 ER - TY - JOUR AU - Bourdage, J. S. AU - Cook, C. A. AU - Farrington, D. L. AU - Chain, J. S. AU - Konrad, R. J. PY - 2007 DA - 2007// TI - An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug JO - J Immunol Methods VL - 327 UR - https://doi.org/10.1016/j.jim.2007.07.004 DO - 10.1016/j.jim.2007.07.004 ID - Bourdage2007 ER - TY - STD TI - Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11. https://doi.org/10.3389/fimmu.2020.01951. ID - ref14 ER - TY - JOUR AU - Bivi, N. AU - Swearingen, C. A. AU - Shockley, T. E. AU - Sloan, J. H. AU - Pottanat, T. G. AU - Carter, Q. L. PY - 2020 DA - 2020// TI - Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity JO - J Immunol Methods VL - 486 UR - https://doi.org/10.1016/j.jim.2020.112856 DO - 10.1016/j.jim.2020.112856 ID - Bivi2020 ER - TY - JOUR AU - Kovalova, N. AU - Knierman, M. D. AU - Brown-Augsburger, P. L. AU - Wroblewski, V. J. AU - Chlewicki, L. K. PY - 2019 DA - 2019// TI - Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque JO - Immunogenetics VL - 71 UR - https://doi.org/10.1007/s00251-019-01136-7 DO - 10.1007/s00251-019-01136-7 ID - Kovalova2019 ER - TY - JOUR AU - Xiang, Y. AU - Parng, C. AU - Olson, K. AU - Seletskaia, E. AU - Gorovits, B. AU - Jani, D. PY - 2019 DA - 2019// TI - Neutralizing antibody assay development with high drug and target tolerance to support clinical development of an anti-TFPI therapeutic monoclonal antibody JO - AAPS J VL - 21 UR - https://doi.org/10.1208/s12248-019-0320-3 DO - 10.1208/s12248-019-0320-3 ID - Xiang2019 ER - TY - JOUR AU - Chen, Y. Q. AU - Pottanat, T. G. AU - Carter, Q. L. AU - Troutt, J. S. AU - Konrad, R. J. AU - Sloan, J. H. PY - 2016 DA - 2016// TI - Affinity capture elution bridging assay: a novel immunoassay format for detection of anti-therapeutic protein antibodies JO - J Immunol Methods VL - 431 UR - https://doi.org/10.1016/j.jim.2016.02.008 DO - 10.1016/j.jim.2016.02.008 ID - Chen2016 ER - TY - STD TI - Hegg R, Pienkowski T, Chen S, Staroslawska E, Falcon S, Kovalenko N, et al. 273P - Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study. Ann Oncol. 2012;23(ix103). https://doi.org/10.1016/s0923-7534(20)32835-0. ID - ref19 ER - TY - STD TI - Padron IM, Garcia JG, D_ıaz RR, Lenza IC, Nicolas FG. Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer. J Oncol Pharm Pract 2020;0:1–3. doi:https://doi.org/10.1177/1078155220953873. ID - ref20 ER - TY - JOUR AU - Triguero, M. C. AU - Yi, J. -. H. AU - Dere, R. AU - Zhihua, J. Q. AU - Lei, C. AU - Li, Y. PY - 2013 DA - 2013// TI - Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine JO - Bioanalysis VL - 9 UR - https://doi.org/10.4155/bio.13.64 DO - 10.4155/bio.13.64 ID - Triguero2013 ER - TY - JOUR AU - Xavier, P. AU - Hii, C. S. J. AU - Mclendon, K. AU - Feyaerts, P. AU - Felicia, A. AU - Demarchi, M. F. PY - 2020 DA - 2020// TI - A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA) JO - Ann Oncol VL - 31 UR - https://doi.org/10.1016/j.annonc.2020.08.288 DO - 10.1016/j.annonc.2020.08.288 ID - Xavier2020 ER - TY - JOUR AU - Kayser, V. AU - Chennamsetty, N. AU - Voynov, V. AU - Helk, B. AU - Trout, B. L. AU - Kayser, V. PY - 2011 DA - 2011// TI - Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding JO - MAbs VL - 4 UR - https://doi.org/10.4161/mabs.3.4.15677 DO - 10.4161/mabs.3.4.15677 ID - Kayser2011 ER - TY - JOUR AU - Dhillon, S. PY - 2018 DA - 2018// TI - ABP 980: A Trastuzumab Biosimilar JO - BioDrugs VL - 32 UR - https://doi.org/10.1007/s40259-018-0305-2 DO - 10.1007/s40259-018-0305-2 ID - Dhillon2018 ER - TY - JOUR AU - Lamb, Y. N. PY - 2018 DA - 2018// TI - SB3 (Ontruzant®): A Trastuzumab Biosimilar JO - BioDrugs VL - 32 UR - https://doi.org/10.1007/s40259-018-0282-5 DO - 10.1007/s40259-018-0282-5 ID - Lamb2018 ER - TY - JOUR AU - Pivot, X. AU - Bondarenko, I. AU - Nowecki, Z. AU - Dvorkin, M. AU - Trishkina, E. AU - Ahn, J. H. PY - 2018 DA - 2018// TI - A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results JO - Eur J Cancer VL - 93 UR - https://doi.org/10.1016/j.ejca.2018.01.072 DO - 10.1016/j.ejca.2018.01.072 ID - Pivot2018 ER - TY - JOUR AU - Lammers, P. E. AU - Dank, M. AU - Masetti, R. AU - Abbas, R. AU - Hilton, F. AU - Coppola, J. PY - 2018 DA - 2018// TI - Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer JO - Br J Cancer VL - 119 UR - https://doi.org/10.1038/s41416-018-0147-1 DO - 10.1038/s41416-018-0147-1 ID - Lammers2018 ER - TY - JOUR AU - Wang, J. AU - Niu, S. AU - Dong, W. AU - Wei, L. AU - Ou, L. AU - Zhang, T. PY - 2020 DA - 2020// TI - A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults JO - Expert Opin Investig Drugs VL - 29 UR - https://doi.org/10.1080/13543784.2020.1770226 DO - 10.1080/13543784.2020.1770226 ID - Wang2020 ER - TY - STD TI - Onda M. Reducing the Immunogenicity of Protein Therapeutics 2009:131–139. ID - ref29 ER - TY - STD TI - Harding FA, Stickler MM, Razo J, Dubridge R, Harding FA, Stickler MM, et al. The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions. 2010;0862. https://doi.org/10.4161/mabs.2.3.11641. ID - ref30 ER - TY - JOUR AU - Qu, Z. AU - Griffiths, G. L. AU - Wegener, W. A. AU - Chang, C. H. AU - Govindan, S. V. AU - Horak, I. D. PY - 2005 DA - 2005// TI - Development of humanized antibodies as cancer therapeutics JO - Methods VL - 36 UR - https://doi.org/10.1016/j.ymeth.2005.01.008 DO - 10.1016/j.ymeth.2005.01.008 ID - Qu2005 ER - TY - JOUR AU - Kijlstra, A. AU - Knutson, D. W. AU - VDL, A. AU - AVE, L. PY - 1977 DA - 1977// TI - Characteristics of soluble immune complexes prepared from oligovalent DNP conjugates and Anti-DNP Antibodies JO - J Immunol Methods VL - 17 UR - https://doi.org/10.1017/CBO9781107415324.004 DO - 10.1017/CBO9781107415324.004 ID - Kijlstra1977 ER - TY - STD TI - Karakoyun I, Arslan FD, Onur S, Ozturk YK, Parildar H, et al. Comparison of 30 Biochemical Analytes in 3 Different Blood Collection Tubes. Türk Klinik Biyokimya Derg. 2020;18:61–9. ID - ref33 ER - TY - JOUR AU - Hurst, S. AU - Ryan, A. M. AU - Ng, C. K. AU - McNally, J. M. AU - Lorello, L. G. AU - Finch, G. L. PY - 2014 DA - 2014// TI - Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®) JO - BioDrugs VL - 28 UR - https://doi.org/10.1007/s40259-014-0103-4 DO - 10.1007/s40259-014-0103-4 ID - Hurst2014 ER - TY - STD TI - Patra S, Young V, Llewellyn L, Senapati JN, Mathew J. BRAF, KRAS and PIK3CA mutation and sensitivity to Trastuzumab in breast cancer cell line model. Asian Pacific J Cancer Prev 2017;18:2209–13. doi:https://doi.org/10.22034/APJCP.2017.18.8.2209. ID - ref35 ER - TY - JOUR AU - Scaltriti, M. AU - Verma, C. AU - Guzman, M. AU - Jimenez, J. AU - Parra, J. L. AU - Pedersen, K. PY - 2009 DA - 2009// TI - Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity JO - Oncogene VL - 28 UR - https://doi.org/10.1038/onc.2008.432 DO - 10.1038/onc.2008.432 ID - Scaltriti2009 ER - TY - JOUR AU - Abo-zeid, M. A. AU - Abo-elfadl, M. T. AU - Gamal-Eldeen, A. M. PY - 2019 DA - 2019// TI - Trastuzumab augments apoptotic cell death of MCF-7 and MDA-MB-231 breast Cancer cell lines JO - J Pharm Sci Res VL - 11 ID - Abo-zeid2019 ER -